Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.

@article{Edmonson1993RandomizedCO,
  title={Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.},
  author={John H. Edmonson and Louise M.. Ryan and Ronald H. Blum and John S J Brooks and Masanori Shiraki and Stephen Frytak and David R. Parkinson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1993},
  volume={11 7},
  pages={1269-75}
}
PURPOSE This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin. PATIENTS AND METHODS Between December 1987 and July 1990, 279 patients with histologically confirmed sarcomas were enrolled to receive treatment A (doxorubicin 80 mg/m2), treatment B (ifosfamide 7.5 g/m2 plus… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 125 extracted citations

Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).

Annals of oncology : official journal of the European Society for Medical Oncology • 1998
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…